SAR442970/Brivekimig Starts a Phase IIΔ Trial In Honeymooners (T1D OBTAIN)

The treatment being tested is called Brivekimig (previously SAR442970). It is a type of biologic drug known as a bispecific nanobody. It is a small, engineered protein designed to bind to and block two specific molecules in the immune system simultaneously: Tumor Necrosis Factor-alpha (TNF-alpha) and OX40 Ligand (OX40L). TNF-alpha and OX40L are two of the chemical messengers that help coordinate…